Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Manual for Electric Vehicles that will be hot dealers in 2023 - 2Exhaustive Experiences into Prudent Senior Living in the UK
- 3Must-Have Cooking Machine in Your Kitchen
- 45 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 5Exploring the School Application Cycle: Understudy Bits of knowledge
- Most loved Seared Chicken: Which Chain Rules?
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- Dirty soda started as a Mormon alternative to booze. Now it's everywhere.
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Exemplary Fragrances: A Manual for Notorious Scents
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- King Charles III says he is reducing cancer treatment schedule in 2026
- Optimal Beauty Parlor Medicines for Upgraded Wellbeing and Appearance
